Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR3 | P51677 | 2/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.84 |
| ▸ | ATM | Q13315 | 4/20 | 0.77 |
| ▸ | GAA | P10253 | 2/20 | 0.77 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.77 |
| ▸ | GLA | P06280 | 1/20 | 0.77 |
| ▸ | MAPT | P10636 | 1/20 | 0.77 |
| ▸ | HTT | P42858 | 1/20 | 0.77 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.77 |
| ▸ | PRMT3 | O60678 | 1/20 | 0.67 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.67 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.67 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.67 |
| ▸ | PRMT8 | Q9NR22 | 1/20 | 0.67 |
| ▸ | ACHE | P22303 | 1/20 | 0.65 |
| ▸ | MEN1 | O00255 | 1/20 | 0.63 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.63 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7977320 | 0.98 | CCR3 (0.96) | CCR3ALDH1A1ATMGAAKDM4E | |
| SCHEMBL8191786 | 0.98 | CCR3 (0.96) | CCR3ALDH1A1ATMGAAKDM4E | |
| SCHEMBL12642472 | 0.90 | CCR3 (0.81) | CCR3ALDH1A1ATMGAAKDM4E | |
| SCHEMBL3148583 | 0.90 | CCR3 (0.81) | CCR3ALDH1A1ATMGAAKDM4E | |
| SCHEMBL8251054 | 0.90 | CCR3 (0.81) | CCR3ALDH1A1ATMGAAKDM4E | |
| SCHEMBL3246849 | 0.90 | CCR3 (0.81) | CCR3ALDH1A1ATMGAAKDM4E | |
| SCHEMBL23719076 | 0.89 | CCR3 (0.80) | CCR3ALDH1A1ATMGAAKDM4E | |
| SCHEMBL6218861 | 0.89 | CCR3 (0.80) | CCR3ALDH1A1ATMGAAKDM4E | |
| SCHEMBL8262506 | 0.89 | CCR3 (0.80) | CCR3ALDH1A1ATMGAAKDM4E | |
| Hydrochloric Acid SCHEMBL7983430 | 0.89 | CCR3 (0.79) | CCR3ALDH1A1ATMGAAKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 51 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0869792-A4 | 4-SUBSTITUTED PIPERIDINE ANALOGS AND THEIR USE AS SUBTYPE SELECTIVE NMDA RECEPTOR ANTAGONISTS | WARNER LAMBERT CO (US) | 1999-09-22 | — | — | EP | claimed |
| US-5912350-A | Certain aminomethyl biphenyl, aminomethyl phenyl pyridine and aminomethyl phenyl pyrimidine derivatives; novel dopamine receptor subtype selective ligands | NEUROGEN CORPORATION (US) | 1999-06-15 | — | — | US | claimed |
| EP-0869792-A2 | 4-SUBSTITUTED PIPERIDINE ANALOGS AND THEIR USE AS SUBTYPE SELECTIVE NMDA RECEPTOR ANTAGONISTS | WARNER-LAMBERT COMPANY (US) | 1998-10-14 | — | — | EP | claimed |
| WO-1997023216-A1 | 4-SUBSTITUTED PIPERIDINE ANALOGS AND THEIR USE AS SUBTYPE SELECTIVE NMDA RECEPTOR ANTAGONISTS | WARNER-LAMBERT COMPANY (US) | 1997-07-03 | — | — | WO | claimed |
| US-20170226072-A1 | 1,4-Disubstituted Piperidines, 1,4-Disubstituted Piperazines, 1,4-Disubstituted Diazepines, and 1,3-Disubstituted Pyrrolidine Compounds | UNIV KENTUCKY RES FOUND (US) | 2017-08-10 | — | — | US | disclosed |
| US-20160031840-A1 | 1,4-Disubstituted Piperidines, 1,4-Disubstituted Piperazines, 1,4-Disubstituted Diazepines, and 1,3-Disubstituted Pyrrolidine Compounds | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION | 2016-02-04 | — | — | US | disclosed |
| EP-1857471-B1 | POLYMERIZATION CATALYST COMPOSITION AND PROCESS FOR PRODUCTION OF POLYMER | MITSUI CHEMICALS INC (JP) | 2013-04-24 | — | — | EP | disclosed |
| US-7960305-B2 | a mixture of a phosphazenium compound such as tetrakis[tris(dimethylamino)phosphoranylideneamino]phosphonium chloride, transition metal halides and an organic halogen compound as an activator, used for addition homo/copolymerization; living polymers | MITSUI CHEMICALS, INC. (JP) | 2011-06-14 | — | — | US | disclosed |
| CN-101128491-B | Polymerization catalyst composition and method for producing polymer | MITSUI CHEMICALS INC | 2010-09-08 | — | — | CN | disclosed |
| US-20080177014-A1 | Polymerization Catalyst Composition and Process for Production of Polymer | MITSUI CHEMICALS, INC. (JP) | 2008-07-24 | — | — | US | disclosed |
| CN-101128491-A | Polymerization catalyst composition and method for producing polymer | MITSUI CHEMICALS INC (JP) | 2008-02-20 | — | — | CN | disclosed |
| EP-1857471-A1 | POLYMERIZATION CATALYST COMPOSITION AND PROCESS FOR PRODUCTION OF POLYMER | Mitsui Chemicals, Inc. (JP) | 2007-11-21 | — | — | EP | disclosed |
| CN-1177957-A | Indole derivatives for the treatment of osteoporosis | SMITHKLINE BEECHAM SPA (IT) | 1998-04-01 | — | — | CN | disclosed |
| US-5726165-A | HYPOGLYCEMIC AGENTS; DIETETICS; GASTROINTESTINAL DISORDERS | SMITHKLINE BEECHAM P.L.C. (GB) | 1998-03-10 | — | — | US | disclosed |
| WO-1998001436-A1 | HETEROAROMATIC PENTADIENOIC ACID DERIVATIVES USEFUL AS INHIBITORS OF BONE RESORPTION | SMITHKLINE BEECHAM S.P.A. (IT) | 1998-01-15 | — | — | WO | disclosed |
| WO-1998001443-A1 | INDOLE DERIVATIVES FOR THE TREATMENT OF OSTEOPOROSIS | SMITHKLINE BEECHAM S.P.A. (IT) | 1998-01-15 | — | — | WO | disclosed |
| US-5677454-A | DIAGNOSIS, THERAPY OF SCHIZOPHRENIA, DEPRESSION, PARKINSONISM | NEUROGEN CORPORATION (US) | 1997-10-14 | — | — | US | disclosed |
| CN-1159797-A | Aryloxy and arylthiopropanolamine derivative suseful as beta 3-adrenoreceptor agonists and antagonists of the beta 1 and beta 2-adrenoreceptors and pharmaceutical composition thereof | SMITHKLINE BEECHAM PLC (GB) | 1997-09-17 | — | — | CN | disclosed |
| WO-1997023216-A1 | 4-SUBSTITUTED PIPERIDINE ANALOGS AND THEIR USE AS SUBTYPE SELECTIVE NMDA RECEPTOR ANTAGONISTS | WARNER-LAMBERT COMPANY (US) | 1997-07-03 | — | — | WO | disclosed |
| WO-1996004234-A1 | ARYLOXY ANDARYCTHIO PROPANOLAMINE DERIVATIVES USEFUL AS B3-ADRENORECEPTOR AGONISTS AND ANTAGONS OF THE B1 AND B2 ADRENORECEPTORS AND PHARMACEUTICAL COMPOSITION THEREOF | SMITHKLINE BEECHAM PLC (GB) | 1996-02-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160031840-A1 | 1,4-Disubstituted Piperidines, 1,4-Disubstituted Piperazines, 1,4-Disubstituted Diazepines, and 1,3-Disubstituted Pyrrolidine Compounds | GRM1, BRD4, DRD1 | CCR3 1466/4885ALDH1A1 378/4885ATM 4718/4885 |
| US-20170226072-A1 | 1,4-Disubstituted Piperidines, 1,4-Disubstituted Piperazines, 1,4-Disubstituted Diazepines, and 1,3-Disubstituted Pyrrolidine Compounds | GRM1, BRD4, DRD1 | CCR3 1466/4885ALDH1A1 378/4885ATM 4718/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.